Venkatesh Murthy, Edward Ficaro, Jeffery Meden, Eric White and James Corbett, Journal of Nuclear Medicine, May 2014, 55 (supplement 1) 1781.
Description:
This study evaluated the relationships between changes in quantitative FDG PET findings and clinical status and treatment in patients with cardiac sarcoidosis. Researchers analyzed 39 FDG PET exams from 16 patients, measuring peak left ventricular SUV (SUVmax) and the percentage of LV myocardium with SUV>2.5 (SUV2.5%) and correlated these findings with clinical status and immunosuppressive treatment regimens.
Clinical Relevance:
The study found significant associations between clinical status and FDG PET parameters, with lower SUVmax and SUV2.5% correlating with stable or improving clinical conditions. Additionally, increased SUVmax was noted with tapered treatment, suggesting FDG PET can serve as a useful tool for monitoring disease activity and guiding treatment decisions in cardiac sarcoidosis.
